ProCE Banner Activity

MCL: Prognostic and Predictive Biomarkers for Risk Stratification and Treatment Selection for Patients

Slideset Download

Download these slides from a live symposium at ASH 2022 to gain more insight into the role of prognostic and predictive biomarkers in the management of patients with MCL.

Released: December 12, 2022

Expiration: December 11, 2023

No longer available for credit.

Share

Faculty

John P. Leonard

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Bristol Myers Squibb

Genmab US Inc and AbbVie

Karyopharm Therapeutics Inc.

Regeneron Pharmaceuticals, Inc.

Program Director Disclosure

Program Director

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York